Reactive arthritis after Gam-COVID-Vac vaccination: A case report

Shokraee, Kamyar; Rezaei, Somaye Sadat; Shahriarian, Shahriar; Masoumi, Maryam; Parsaei, Amirhossein; Amini, Behnam

doi:10.1093/mrcr/rxad002

Cited by 5 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reactive Arthritis Out of 30 reactive arthritis (ReA) patients, the majority presented with oligoarthritis (17,56%) [121], followed by monoarthritis (7, 23%) [9,29,69,97,98,107,135], and polyarthritis (6,20%) [86,98,158,169]. Among the patients with monoarthritis, four had knee joints affected [9,97,98,135], two had elbow joints affected [69,107], and one had ankle joints affected [29]. CRP was raised in 20 patients, between 10 and 237.…”

Section: Subacute Cutaneous Lupusmentioning

confidence: 99%

“…A total of twenty-five patients received corticosteroids, two nonsteroidal anti-inflammatory drugs (NSAIDs) [98], and three patients received a combination of NSAIDs and corticosteroids [69,97,158]. Of the twenty-eight patients who received corticosteroids, most received oral corticosteroids (twenty-two patients) [29,86,98,121,169], four received intraarticular (IA) corticosteroids [9,67,97,107], one received intramuscular corticosteroid (IM) [158], and one received IV corticosteroids.…”

Section: Subacute Cutaneous Lupusmentioning

confidence: 99%

See 1 more Smart Citation

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Nune,

Durkowski,

Pillay

et al. 2023

Vaccines

View full text Add to dashboard Cite

A comprehensive, up-to-date systematic review (SR) of the new-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccinations is lacking. Therefore, we investigated the demographics, management, and prognosis of new R-IMIDs in adults following SARS-CoV-2 vaccinations. A systematic literature search of Medline, Embase, Google Scholar, LitCovid, and Cochrane was conducted. We included any English-language study that reported new-onset R-IMID in adults following the post-COVID-19 vaccination. A total of 271 cases were reported from 39 countries between January 2021 and May 2023. The mean age of patients was 56 (range 18–90), and most were females (170, 62.5%). Most (153, 56.5%) received the Pfizer BioNTech COVID-19 vaccine. Nearly 50% of patients developed R-IMID after the second dose of the vaccine. Vasculitis was the most prevalent clinical presentation (86, 31.7%), followed by connective tissue disease (66, 24.3%). The mean duration between the vaccine’s ‘trigger’ dose and R-IMID was 11 days. Most (220, 81.2%) received corticosteroids; however, 42% (115) received DMARDs such as methotrexate, cyclophosphamide, tocilizumab, anakinra, IV immunoglobulins, plasma exchange, or rituximab. Complete remission was achieved in 75 patients (27.7%), and 137 (50.6%) improved following the treatment. Two patients died due to myositis. This SR highlights that SARS-CoV-2 vaccines may trigger R-IMID; however, further epidemiology studies are required.

show abstract

Section: Subacute Cutaneous Lupusmentioning

confidence: 99%

Section: Subacute Cutaneous Lupusmentioning

confidence: 99%

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Nune,

Durkowski,

Pillay

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Reactive arthritis (ReA), previously referred to as Reiter's syndrome, is a type of seronegative spondyloarthritis (SpA) classically caused by genitourinary and gastrointestinal infections, but ReA can also develop after intravesical Bacillus Calmette-Guerin (BCG) therapy, COVID-19, and certain vaccinations [1–5,6 ▪▪ ,7–11]. ReA typically resolves within 3–5 months, but a fraction of patients develop chronic arthritis and up to 40% develop sacroiliitis, erosive arthritis, or iritis [1,12].…”

Section: Reactive Arthritismentioning

confidence: 99%

Management of postinfectious inflammatory arthritis

Baker,

Amaral,

Schoen

2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Postinfectious inflammatory arthritis can result from various pathogens, including bacteria, viruses, fungi, and parasites. Prompt identification and treatment of acute infection is vital, but some cases progress to chronic arthritis despite successful treatment of infection. Postinfectious inflammatory arthritis varies from mild, self-limited arthralgia to severe, refractory arthritis, necessitating ongoing disease-modifying treatment. This review explores the spectrum of postinfectious inflammatory arthritis to provide insights into effective management. Recent findings Research continues regarding the benefit of antimicrobial therapy, beyond treatment of the acute infection, to diminish the severity of postinfectious inflammatory arthritis. Following treatment of acute infection, most cases are self-limited so treatment is symptomatic. However, a difficult-to-predict fraction of cases develop chronic postinfectious inflammatory arthritis that can be challenging to manage. Recently, as more biologic, and targeted synthetic DMARDs have become available, treatment options have expanded. Summary In this article, we use the term ‘postinfectious inflammatory arthritis’ rather than ‘reactive arthritis’ because it describes a broader spectrum of diseases and emphasizes the common pathogenesis of a postinfectious inflammatory process. We summarize the conventional therapies and recent management developments for the most frequently encountered postinfectious inflammatory arthritides.

show abstract

“…Recent reports have surfaced regarding cases of autoimmune diseases following the administration of the Sputnik vaccine. These include reactive arthritis, thrombocytopenia, thrombosis, severe eczema, and neurological manifestations such as Bell's palsy and demyelinating diseases or relapses of multiple sclerosis, among others [8][9][10][11][12]. The mechanisms underlying the development of adverse effects like thrombosis due to the Sputnik vaccine remain unclear but may be similar to those proposed for the AstraZeneca vaccine (AstraZeneca: AZ, Cambridge, UK).…”

Section: Introductionmentioning

confidence: 97%

New Onset Autoimmune Diseases after the Sputnik Vaccine

et al. 2023

View full text Add to dashboard Cite

The vertiginous advance for identifying the genomic sequence of SARS-CoV-2 allowed the development of a vaccine including mRNA-based vaccines, inactivated viruses, protein subunits, and adenoviral vaccines such as Sputnik. This study aims to report on autoimmune disease manifestations that occurred following COVID-19 Sputnik vaccination. Patients and Methods: A retrospective study was conducted on patients with new-onset autoimmune diseases induced by a post-COVID-19 vaccine between March 2021 and December 2022, in two referral hospitals in Mexico City and Argentina. The study evaluated patients who received the Sputnik vaccine and developed recent-onset autoimmune diseases. Results: Twenty-eight patients developed recent-onset autoimmune diseases after Sputnik vaccine. The median age was 56.9 ± 21.7 years, with 14 females and 14 males. The autoimmune diseases observed were neurological in 13 patients (46%), hematological autoimmune manifestations occurred in 12 patients (42%), with thrombotic disease observed in 10 patients (28%), and autoimmune hemolytic anemia in two patients (7.1%). Rheumatological disorders were present in two patients (7.1%), and endocrine disorders in one patient (3.5%). Principio del formulario Conclusion: Although the COVID-19 Sputnik vaccine is generally safe, it can lead to adverse effects. Thrombosis and Guillain-Barre were the most frequent manifestations observed in our group of patients.

show abstract

Reactive arthritis after Gam-COVID-Vac vaccination: A case report

Cited by 5 publications

References 4 publications

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Management of postinfectious inflammatory arthritis

New Onset Autoimmune Diseases after the Sputnik Vaccine

Contact Info

Product

Resources

About